Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Columbia University Irving Medical Center

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1202
Shown on this page
12
Current sort
Recently updated
Campus scope
Columbia University Irving Medical Center, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Columbia University Irving Medical Center, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 277–288 of 1,202 matching trials with a site at Columbia University Irving Medical Center, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 3 Interventional

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

NCT03257033
Site status not listed — check the official record
View directory record Official record
Conditions
Locally Advanced Pancreatic Cancer
Interventions
Gemcitabine, nab-paclitaxel, RenovoCath
Drug · Device
Lead sponsor
RenovoRx
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
26
States / cities
Loma Linda, California • Sacramento, California • Washington D.C., District of Columbia + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 22, 2026, 6:39 PM EDT
Active, not recruiting Not applicable Interventional

HPV Vaccine Reminders - SEARCH II Study

NCT06161831
Site status not listed — check the official record
View directory record Official record
Conditions
Human Papillomavirus Vaccination
Interventions
Text Message/automated phone reminder
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
10 Years to 14 Years · Female only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 22, 2026, 6:39 PM EDT
Recruiting Not applicable Interventional

Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

NCT05102019
Status at this site: Recruiting
View directory record Official record
Conditions
Refractory Angina
Interventions
Arm 1: treatment with Shockwave Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry
Device · Other
Lead sponsor
Shockwave Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
72
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 22, 2026, 6:39 PM EDT
Recruiting Phase 3 Interventional

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

NCT07197944
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Glepaglutide, Placebo
Drug · Other
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 90 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
6
States / cities
Chicago, Illinois • St Louis, Missouri • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 6:39 PM EDT
Active, not recruiting Phase 3 Interventional

Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

NCT05968430
Site status not listed — check the official record
View directory record Official record
Conditions
Hypertension
Interventions
lorundrostat, Placebo
Drug
Lead sponsor
Mineralys Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,076 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
128
States / cities
Birmingham, Alabama • Foley, Alabama • Chandler, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 6:39 PM EDT
Recruiting Phase 3 Interventional

ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

NCT05878860
Status at this site: Recruiting
View directory record Official record
Conditions
X-linked Retinoschisis
Interventions
ATSN-201
Biological
Lead sponsor
Atsena Therapeutics Inc.
Industry
Eligibility
5 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
18
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 6:39 PM EDT
Active, not recruiting Phase 3 Interventional

REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome

NCT06914609
Site status not listed — check the official record
View directory record Official record
Conditions
Angelman Syndrome
Interventions
obudanersen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 50 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
18
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 6:39 PM EDT
Active, not recruiting Phase 1 Interventional

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

NCT05079282
Site status not listed — check the official record
View directory record Official record
Conditions
Relapsed or Refractory T Cell Lymphoma
Interventions
ONO-4685
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Duarte, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 6:39 PM EDT
Recruiting Phase 1 Interventional

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

NCT05803382
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Malignant Solid Neoplasm
Interventions
BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
22
States / cities
Irvine, California • Orange, California • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 6:39 PM EDT
Recruiting Not applicable Interventional

Preoperative Music Intervention for Anxiety in Hip and Knee Arthroplasty

NCT07845695
Status at this site: Recruiting
View directory record Official record
Conditions
Anxiety, Osteoarthritis
Interventions
Music via Headphones
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 6:39 PM EDT
Recruiting Phase 1 Interventional

A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors

NCT07107230
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Stage Solid Tumors
Interventions
JNJ-95437446, Amivantamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Sarasota, Florida • New York, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 6:39 PM EDT
Active, not recruiting Phase 2 Interventional

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

NCT03598257
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Inflammatory Carcinoma
Interventions
Biospecimen Collection, Olaparib, Radiation Therapy, Survey Administration
Procedure · Drug · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
214
States / cities
Anchorage, Alaska • Gilbert, Arizona • Tucson, Arizona + 174 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 6:39 PM EDT

About this Columbia University Irving Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Columbia University Irving Medical Center in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.